PET Scan Test for Spread of High-risk Prostate Cancer to Lymph Nodes
Tests a PET scan tracer to detect prostate cancer spread to lymph nodes in adults.
Plain-language title generated from the registry record
Registry title: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Key facts
- Where
- Murdoch, Nedlands, Sydney, and Woolloongabba, AustraliaSee the 4 sites
- Phase
- Phase 3
Where in Australia
- Fiona Stanley HospitalMurdoch, AustraliaTaking people
- RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private HospitalNedlands, AustraliaTaking people
- St. Vincent's SydneySydney, AustraliaTaking people
- Princess Alexandra HospitalWoolloongabba, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Clarity Pharmaceuticals Ltd
- Trial code
- NCT06056830
- Record updated
- 11 September 2026
- Original description
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.Read full original descriptionShow less
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Inclusion: At least 18 years of age; Signed informed consent; Untreated, histologically confirmed adenocarcinoma of the prostate; High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA >20 ng/mL); Patients electing to undergo RP with PLND.
Exclusion: Administration of any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1; Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components; Patients with known predominant small cell or neuroendocrine PC.